Additionally, p-ERK1/2 levels were lower after simultaneous exposure to FTD (1.0 μM or 4.0 μM) and regorafenib (10.0 μM) for 24 h or sequential exposure to FTD (1.0 μM or 4.0 μM) for 24 h followed by regorafenib (10.0 μM) for 24 h than the levels in untreated control cells. The gene discussed is MAPK3; the disease is frontotemporal dementia.